Virax Biolabs Group Limited Ordinary Shares (VRAX) Stock Price

VRAXStock

$2.91−84.31%52W

Market Cap$2.32M

P/E—

PEG Ratio—

Div yield—

Beta1.44

VRAX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-56.20%

Price vs S&P 500 (4W)0.75%

VGM Score41.89

Book Value / Share (Quarterly)$13.08

P/TBV (Annual)0.32x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)13.21%

Cash Flow / Share (Quarterly)$-8.42

Price vs S&P 500 (YTD)-77.24%

Gross Margin (TTM)61.95%

Net Profit Margin (TTM)-40416.33%

EPS (TTM)$-23.09

10-Day Avg Trading Volume1.90M

EPS Excl Extra (TTM)$-23.09

Revenue Growth (5Y)-36.47%

EPS (Annual)$-12.64

ROI (Annual)-62.86%

Gross Margin (Annual)61.92%

Net Profit Margin (5Y Avg)-40961.08%

Cash / Share (Quarterly)$11.12

Revenue Growth QoQ (YoY)684.06%

ROA (Last FY)-60.35%

Revenue Growth TTM (YoY)96.37%

EBITD / Share (TTM)$-27.16

Operating Margin (TTM)-51486.08%

Cash Flow / Share (Annual)$-8.42

P/B Ratio0.26x

P/B Ratio (Quarterly)0.26x

Net Income / Employee (Annual)$-264,400

EV / Revenue (TTM)-325.82x

Net Interest Coverage (TTM)-105.63x

ROA (TTM)-71.56%

EPS Incl Extra (Annual)$-12.64

Current Ratio (Annual)9.97x

Quick Ratio (Quarterly)9.44x

3-Month Avg Trading Volume1.77M

52-Week Price Return-84.31%

Revenue / Employee (TTM)$700

Tangible BV / Share (Quarterly)$2.09

P/S Ratio (Annual)158.99x

Asset Turnover (Annual)0.00x

52-Week High$21.75

Operating Margin (5Y Avg)-44109.17%

EPS Excl Extra (Annual)$-12.64

26-Week Price Return-44.95%

Quick Ratio (Annual)9.44x

13-Week Price Return-60.78%

Total Debt / Equity (Annual)0.05x

Current Ratio (Quarterly)9.97x

Enterprise Value$-4.05M

Revenue / Share Growth (5Y)24.10%

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$700

Inventory Turnover (Annual)0.10x

Pretax Margin (Annual)-47765.06%

Cash / Share (Annual)$11.12

3-Month Return Std Dev244.20%

Gross Margin (5Y Avg)-153.69%

Net Income / Employee (TTM)$-264,400

ROE (Last FY)-66.30%

Net Interest Coverage (Annual)-92.23x

EPS Basic Excl Extra (Annual)$-12.64

Receivables Turnover (TTM)1.94x

Total Debt / Equity (Quarterly)0.05x

EPS Incl Extra (TTM)$-23.09

ROI (TTM)-72.59%

P/S Ratio (TTM)158.86x

Pretax Margin (5Y Avg)-42879.67%

Revenue / Share (Annual)$0.03

Tangible BV / Share (Annual)$52.12

Price vs S&P 500 (52W)-102.62%

Year-to-Date Return-65.28%

5-Day Price Return8.70%

EPS Normalized (Annual)$-12.64

ROA (5Y Avg)-750.61%

Net Profit Margin (Annual)-40448.87%

Month-to-Date Return14.50%

EBITD / Share (Annual)$-14.99

Operating Margin (Annual)-51527.62%

EPS Basic Excl Extra (TTM)$-23.09

P/TBV (Quarterly)0.32x

P/B Ratio (Annual)0.26x

Inventory Turnover (TTM)0.10x

Pretax Margin (TTM)-47726.71%

Book Value / Share (Annual)$13.08

Price vs S&P 500 (13W)-63.58%

Beta1.44x

Revenue / Share (TTM)$0.05

ROE (TTM)-77.95%

52-Week Low$2.50

gGradeB

mGradeD

vgmGradeC

VRAX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

Industry Peers — In Vitro Diagnostics(18)

Symbol	Value Score	Growth Score	Momentum Score	Price
VRAXVirax Biolabs Group Limited Ordinary Shares	—	B	D	$2.91
IDXXIdexx Laboratories Inc	D	B	C	$550.01
LNTHLantheus Holdings, Inc	C	B	B	$100.87
CLDXCelldex Therapeutics, Inc	F	F	B	$41.22
NEOGNeogen Corp	C	C	B	$11.64
NTLAIntellia Therapeutics, Inc	D	D	C	$13.51
QDELQuidelOrtho Corporation Common Stock	C	C	C	$15.05
ACHVAchieve Life Sciences, Inc.	F	F	A	$8.17
TKNOAlpha Teknova, Inc. Common Stock	D	C	A	$7.46
NNNNAnbio Biotechnology Class A Ordinary Shares	F	B	F	$7.83
MYGNMyriad Genetics Inc	B	C	D	$3.19
IMDXInsight Molecular Diagnostics Inc. Common Stock	F	D	C	$4.44
ICCCImmucell Corp	C	B	B	$9.84
QCLSQ/C Technologies, Inc. Common Stock	C	—	F	$2.44
TRIBTrinity Biotech plc	B	D	F	$9.71
CDIOCardio Diagnostics Holdings Inc. Common stock	—	C	B	$1.91
BMRABIOMERICA INC	B	D	D	$1.77
VNRXVolitionRx Limited	B	A	F	$0.38
CDIOWCardio Diagnostics Holdings Inc. Warrant	—	—	C	$0.01

About Virax Biolabs Group Limited Ordinary Shares

Virax Biolabs is a biotechnology company specializing in immune response detection and viral disease diagnostics. The company offers research-use-only assays and immunology services through its ViraxImmune platform and ImmuneSelect portfolio. It is developing T cell-based diagnostic tests targeting post-acute infection syndromes, including Long COVID and other immune dysregulation-related conditions.